New Dual-Action drug shows promise for PCOS in early trial
NCT ID NCT07616037
First seen May 30, 2026 · Last updated Jun 23, 2026 · Updated 4 times
Summary
This phase 2 trial is testing a new weekly injection called HEC88473 in 30 women with polycystic ovary syndrome (PCOS). The drug targets two pathways (GLP-1 and FGF21) to improve hormone levels, menstrual cycles, and metabolic health. Researchers hope it could become a new treatment option for managing PCOS.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POLYCYSTIC OVARY SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhongshan Hospital, Fudan University
RECRUITINGShanghai, Shanghai Municipality, 201508, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HEC88473 (a GLP-1/FGF21 dual agonist)
What this could lead to
If successful, this could offer a new treatment option for PCOS that improves hormone levels, menstrual regularity, and metabolic health.
What could go wrong
This is a small, early-phase trial with only 30 participants, so results may not apply broadly. The drug may cause side effects or fail to show meaningful benefit.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.